toxicities of immunotherapy and patient expectations in lung cancer
Published 7 years ago • 89 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
4:15
the toxicities associated with immunotherapy in lung cancer patients
-
0:43
the rarer toxicities of immunotherapy
-
2:22
immunotherapy toxicities and checkpoint inhibitor therapy
-
1:55
curbing cancer patients’ expectations of immunotherapy
-
1:43
managing toxicity from immunotherapy
-
1:08
management of immunotherapy toxicity in gynecological cancers
-
2:31
differences in treating lung cancer with adjuvant and neoadjuvant immunotherapy
-
3:16
checkpoint inhibitors - alone or with chemotherapy in lung cancer?
-
0:45
how to discuss immunotherapy as a treatment option with lung cancer patients
-
1:46
predicting response to checkpoint inhibitors and overcoming resistance in lung cancers
-
1:31
the nurse's perspective on caring for lung cancer patients receiving immunotherapy
-
1:46
immunotherapy for lung cancer and trial of ramucirumab plus pembrolizumab
-
3:24
novel immunotherapy agents on the horizon for lung cancer
-
1:03
guiding clinicians to recognize toxicity levels of newer immunotherapy agents
-
0:37
how do side effects from immunotherapy differ from side effects from chemotherapy in lung cancer?
-
3:02
neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer
-
1:48
assessing immunotherapy in various subtypes of lung cancer
-
4:22
immunotherapy-related pulmonary toxicities in melanoma
-
3:18
immune checkpoint inhibitors and combination strategies for patients with gastric cancer